高分子键合康普瑞汀A4血管阻断剂纳米药物

王月; 汤朝晖

doi:10.11777/j.issn1000-3304.2021.21024

您当前的位置：

首页 >

文章列表页 >

高分子键合康普瑞汀A4血管阻断剂纳米药物

专论 | 更新时间：2023-05-22

- 高分子键合康普瑞汀A4血管阻断剂纳米药物
- Polymeric Nanodrug of Vascular Disrupting Agent Combretastatin A4
- 高分子学报 2021年52卷第9期页码：1058-1075
- 作者机构：
  
  中国科学院长春应用化学研究所中国科学院生态环境高分子材料重点实验室　长春 130022
- 作者简介：
  
  E-mail: ztang@ciac.ac.cn
- 基金信息：
  
  国家自然科学基金(基金号 ┣52025035);51873206┫
- DOI：10.11777/j.issn1000-3304.2021.21024
  中图分类号：
- 纸质出版日期：2021-09-20，
  
  网络出版日期：2021-07-05，
  
  收稿日期：2021-01-21，
  
  修回日期：2021-02-25，
扫描看全文
王月,汤朝晖.高分子键合康普瑞汀A4血管阻断剂纳米药物[J].高分子学报,2021,52(09):1058-1075.

Wang Yue,Tang Zhao-hui.Polymeric Nanodrug of Vascular Disrupting Agent Combretastatin A4[J].ACTA POLYMERICA SINICA,2021,52(09):1058-1075.
王月,汤朝晖.高分子键合康普瑞汀A4血管阻断剂纳米药物[J].高分子学报,2021,52(09):1058-1075. DOI： 10.11777/j.issn1000-3304.2021.21024.

Wang Yue,Tang Zhao-hui.Polymeric Nanodrug of Vascular Disrupting Agent Combretastatin A4[J].ACTA POLYMERICA SINICA,2021,52(09):1058-1075. DOI： 10.11777/j.issn1000-3304.2021.21024.

摘要

血管阻断剂(VDAs)因其在实体肿瘤治疗中的巨大潜力而引起人们的广泛关注. 本文针对本课题组近年来在高分子血管阻断剂纳米药物抗肿瘤治疗方面的基础研究进行了总结. 首先发现了纳米药物的瘤内低渗透性可显著提高血管阻断剂的肿瘤血管靶向性和抑瘤能力，进而构建了高分子血管阻断剂纳米药物；其次针对高分子血管阻断剂纳米药物治疗所引起的不利宿主反应，引入小分子抑制剂或激动剂进行联合治疗；然后利用其调控肿瘤微环境并创建肿瘤选择性药物激活递送系统；最后针对其治疗所产生的肿瘤凝血微环境提出了新的主动靶向策略——链式自放大肿瘤靶向，实现了高效的肿瘤靶向药物递送. 这项工作突出了高分子血管阻断剂纳米药物在肿瘤治疗中的潜力，并对其未来研究方向作了简要展望，以促进其临床转化.

Abstract

Vascular disrupting agents (VDAs) have aroused increasing interest due to their great potential in tumor therapy. In this work

recent progresses of our group in the polymeric nanodrug of VDAs are reviewed. As compared to combretastatin A4 phosphate (CA4P)

a small-molecule prodrug of combretastatin A4 which has entered Phase Ⅲ clinical trials

poly(L-glutamic acid)-

-methoxy poly(ethylene glycol)/combretastatin A4 (PLG-CA4 or CA4-NPs) shows significantly improved the tumor blood vessels targeting and enhanced therapeutic effect due to the low permeability of nanodrug in solid tumors. However

the tumor microenvironment changes significantly after CA4-NPs treatment

which can lead to a series of host responses

such as the increased expression of VEGF-A

CXCR4 as well as the polarization of tumor-associated macrophages toward a M2-like phenotype. Several small molecule inhibitors or antagonists were used to combine with CA4-NPs for inhibiting tumor growth and metastasis. As a result

a significant reduction in tumor volume and prolonged survival time of tumor-bearing mice were observed. In addition

the levels of hypoxia and MMP-9 were regulated by using CA4-NPs

and thereby drug controlled release systems with high selectivity to tumor-microenvironment were constructed to achieve drug activation with high tumor selectivity. This significantly enhanced the therapeutic effect of MMP9-activated prodrugs and hypoxia-activated prodrugs. Based on the tumor-specific coagulation microenvironment created by the VDAs

a coagulation targeting peptide (GN

EQVSPLTLLKXC

termed A15)-decorated poly(L-glutamic acid)-graft-maleimide poly(ethylene glycol)/combretastatin A4 conjugate (A15-PLG-CA4) was constructed as a self-amplifying nanotherapeutic tumor homing platform working through a chain reaction mechanism. After administration to tumor-bearing mice

A15-PLG-CA4 started a chain reaction cycle consisting of intratumoral hemorrhage

target FXIIIa amplification

blood clot binding and CA4 release in tumors to achieve a high tumor targeting efficiency. Furthermore

this self-amplifying tumor-targeting platform can be used for the selective delivery of other drugs to tumors. This work highlights the potential of the polymeric nanodrug of combretastatin A4 for tumor therapy. A brief perspective is also provided for future research directions about the VDAs nanodrug.

关键词

血管阻断剂纳米药物谷氨酸自放大肿瘤靶向

Keywords

Vascular disrupting agentsNanodrugGlutamic acidSelf-amplifyingTumor-homing

references

Kanthou C, Tozer G M. Blood, 2002, 99(6): 2060-2069. doi:10.1182/blood.v99.6.2060http://dx.doi.org/10.1182/blood.v99.6.2060

Tang Zhaohui(汤朝晖), Chen Xuesi(陈学思). Acta Polymerica Sinica(高分子学报), 2019, 50(6): 543-552. doi:10.11777/j.issn1000-3304.2019.19036http://dx.doi.org/10.11777/j.issn1000-3304.2019.19036

Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Cancer Res, 1976, 36(8): 2807-2812.

Folkman J. N Engl J Med, 1971, 285(21): 1182-1186. doi:10.1056/nejm197111182852108http://dx.doi.org/10.1056/nejm197111182852108

Folkman J. Cancer Res, 1986, 46(2): 467-473. doi:10.1007/978-1-4684-5050-7_6http://dx.doi.org/10.1007/978-1-4684-5050-7_6

Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Cancer Res, 1999, 59(19): 4770-4775

Kerbel R, Folkman J. Nat Rev Cancer, 2002, 2(10): 727-739. doi:10.1038/nrc905http://dx.doi.org/10.1038/nrc905

Chen D, Qu X, Shao J, Wang W, Dong X. J Mater Chem B, 2020, 8(15): 2990-3004. doi:10.1039/c9tb02957ehttp://dx.doi.org/10.1039/c9tb02957e

Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidi A L, Papadaki A, Zarkavelis G, Mauri D, Karpathiou G, Kolettas E, Batistatou A, Pentheroudakis G. Cancers 2020, 12(11): 3145-3145. doi:10.3390/cancers12113145http://dx.doi.org/10.3390/cancers12113145

Siemann D W, Chaplin D J, Horsman M R. Cancer Invest, 2017, 35(8): 519-534. doi:10.1080/07357907.2017.1364745http://dx.doi.org/10.1080/07357907.2017.1364745

Pettit G R, Singh S B, Hamel E, Lin C M, Alberts D S, Garcia-Kendal D. Experientia, 1989, 45(2): 209-211. doi:10.1007/bf01954881http://dx.doi.org/10.1007/bf01954881

Tozer G M, Kanthou C, Baguley B C. Nat Rev Cancer, 2005, 5(6): 423-435. doi:10.1038/nrc1628http://dx.doi.org/10.1038/nrc1628

Siemann D W. Cancer Treat Rev, 2011, 37(1): 63-74. doi:10.1016/j.ctrv.2010.05.001http://dx.doi.org/10.1016/j.ctrv.2010.05.001

Stevenson J P, Rosen M, Sun W, Gallagher M, Haller D G, Vaughn D, Giantonio B, Zimmer R, Petros W P, Stratford M, Chaplin D, Young S L, Schnall M, O'Dwyer P J. J Clin Oncol, 2003, 21(23): 4428-4438. doi:10.1200/jco.2003.12.986http://dx.doi.org/10.1200/jco.2003.12.986

Tozer G M, Prise V E, Wilson J, Cemazar M, Shan S, Dewhirst M W, Barber P R, Vojnovic B, Chaplin D J. Cancer Res, 2001, 61(17): 6413-6422

Tozer G M, Prise V E, Wilson J, Locke R J, Vojnovic B, Stratford M R L, Dennis M F, Chaplin D J. Cancer Res, 1999, 59(7): 1626-1634

Hua J, Sheng Y, Pinney K G, Garner C M, Kane R R, Prezioso JA, Pettit G R, Chaplin D J, Edvardsen K, Anticancer Res, 2003, 23(2B): 1433-1440

Grosios K, Holwell S E, McGown A T, Pettit G R, Bibby M C. Br J Cancer, 1999, 81(8): 1318-1327. doi:10.1038/sj.bjc.6692174http://dx.doi.org/10.1038/sj.bjc.6692174

Tang Z, He C, Tian H, Ding J, Hsiao B S, Chu B, Chen X. Prog Polym Sci, 2016, 60: 86-128. doi:10.1016/j.progpolymsci.2016.05.005http://dx.doi.org/10.1016/j.progpolymsci.2016.05.005

Bae Y, Park K. J Control Release, 2011, 153(3): 198-205. doi:10.1016/j.jconrel.2011.06.001http://dx.doi.org/10.1016/j.jconrel.2011.06.001

Song W, Tang Z, Zhang D, Yu H, Chen X. Small, 2015, 11(31): 3755-3761. doi:10.1002/smll.201500324http://dx.doi.org/10.1002/smll.201500324

Liu Chang(刘畅), Chen Yuxin(陈宇欣), Wang Jiangfan(王江帆), Luo Xuan(罗萱), Huang Yudi(黄宇迪), Xu Jinlei(徐瑾蕾), Yan Guoping(鄢国平), Chen Si(陈思), Zhang Xianzheng(张先正). Acta Polymerica Sinica(高分子学报), 2018, (6): 682-691. doi:10.11777/j.issn1000-3304.2017.17335http://dx.doi.org/10.11777/j.issn1000-3304.2017.17335

Liu T, Zhang D, Song W, Tang Z, Zhu J, Ma Z, Wang X, Chen X, Tong T. Acta Biomater, 2017, 53: 179-189. doi:10.1016/j.actbio.2017.02.001http://dx.doi.org/10.1016/j.actbio.2017.02.001

Nelson M E, Lahiri S, Chow J D Y, Byrne F L, Hargett S R, Breen D S, Olzomer E M, Wu L E, Cooney G J, Turner N, James D E, Slack-Davis J K, Lackner C, Caldwell S H, Hoehn K L. Nat Commun, 2017, 8: 14689. doi:10.1038/ncomms14689http://dx.doi.org/10.1038/ncomms14689

Shi F, Lian S, Wu P, Shen L. J Clin Oncol, 2017, 35(15_suppl): e15635. doi:10.1200/jco.2017.35.15_suppl.e15635http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15635

Forner A, Reig M, Bruix J. The Lancet, 2018, 391(10127): 1301-1314. doi:10.1016/s0140-6736(18)30010-2http://dx.doi.org/10.1016/s0140-6736(18)30010-2

Forner A, Gilabert M, Bruix J, Raoul J L. Nat Rev Clin Oncol, 2014, 11(9): 525-535. doi:10.1038/nrclinonc.2014.122http://dx.doi.org/10.1038/nrclinonc.2014.122

Madlambayan G J, Meacham A M, Hosaka K, Mir S, Jorgensen M, Scott E W, Siemann D W, Cogle C R. Blood, 2010, 116(9): 1539-1547. doi:10.1182/blood-2009-06-230474http://dx.doi.org/10.1182/blood-2009-06-230474

Ho Y J, Wang T C, Fan C H, Yeh C K. Drug Discov Today, 2017, 22(10): 1503-1515. doi:10.1016/j.drudis.2017.06.001http://dx.doi.org/10.1016/j.drudis.2017.06.001

Wilson M A, Zhao F, Letrero R, D'Andrea K, Rimm D L, Kirkwood J M, Kluger H M, Lee S J, Schuchter L M, Flaherty K T, Nathanson K L. Clinical Cancer Res, 2014, 20(12): 3328-3337. doi:10.1158/1078-0432.ccr-14-0093http://dx.doi.org/10.1158/1078-0432.ccr-14-0093

Cheng A L, Thongprasert S, Lim H Y, Sukeepaisarnjaroen W, Yang T S, Wu C C, Chao Y, Chan S L, Kudo M, Ikeda M, Kang Y K, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez A M, Zhang Y, Wang Y, Poon R T. Hepatology, 2016, 64(3): 774-784. doi:10.1002/hep.28600http://dx.doi.org/10.1002/hep.28600

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau G Y, Mazzaferro V, Roayaie S, Lee H C, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru A E, Cillo U, de la Mata M, Lupo L, Strasser S, Park J W, Camps J, Solé M, Thung S N, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet J M. GUT, 2019, 68(6): 1065-1075. doi:10.1136/gutjnl-2018-316408http://dx.doi.org/10.1136/gutjnl-2018-316408

Wang Y, Yu H, Zhang D, Wang G, Song W, Liu Y, Ma S, Tang Z, Liu Z, Sakurai K, Chen X. Acta Biomater, 2019, 92:229-240. doi:10.1016/j.actbio.2019.05.028http://dx.doi.org/10.1016/j.actbio.2019.05.028

Munn D H, Bronte V. Curr Opin Immunol, 2016, 39: 1-6. doi:10.1016/j.coi.2015.10.009http://dx.doi.org/10.1016/j.coi.2015.10.009

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. Immunol Today, 1992, 13(7): 265-270. doi:10.1016/0167-5699(92)90008-uhttp://dx.doi.org/10.1016/0167-5699(92)90008-u

Franklin R A, Liao W, Sarkar A, Kim M V, Bivona M R, Liu K, Pamer E G, Li M O. Science, 2014, 344(6186): 921-925. doi:10.1126/science.1252510http://dx.doi.org/10.1126/science.1252510

Noy R, Pollard J W. Immunity, 2014, 41(1): 49-61. doi:10.1016/j.immuni.2014.06.010http://dx.doi.org/10.1016/j.immuni.2014.06.010

Qian B Z, Pollard J W. Cell, 2010, 141(1): 39-51. doi:10.1016/j.cell.2010.03.014http://dx.doi.org/10.1016/j.cell.2010.03.014

Ruffell B, Coussens L M. Cancer Cell, 2015, 27(4): 462-472. doi:10.1016/j.ccell.2015.02.015http://dx.doi.org/10.1016/j.ccell.2015.02.015

Qin H, Yu H, Sheng J, Zhang D, Shen N, Liu L, Tang Z, Chen X. Adv Sci, 2019, 6(12): 1900327. doi:10.1002/advs.201900327http://dx.doi.org/10.1002/advs.201900327

Foubert P, Kaneda M M, Varner J A. Cancer Immunol Res, 2017, 5(11): 957-968. doi:10.1158/2326-6066.cir-17-0143http://dx.doi.org/10.1158/2326-6066.cir-17-0143

Schmid M C, Avraamides C J, Dippold H C, Franco I, Foubert P, Ellies L G, Acevedo L M, Manglicmot J R, Song X, Wrasidlo W, Blair S L, Ginsberg M H, Cheresh D A, Hirsch E, Field S J, Varner J A. Cancer Cell, 2011, 19(6): 715-727. doi:10.1016/j.ccr.2011.04.016http://dx.doi.org/10.1016/j.ccr.2011.04.016

Kaneda M M, Messer K S, Ralainirina N, Li H, Leem C J, Gorjestani S, Woo G, Nguyen A V, Figueiredo C C, Foubert P, Schmid M C, Pink M, Winkler D G, Rausch M, Palombella V J, Kutok J, McGovern K, Frazer K A, Wu X, Karin M, Sasik R, Cohen E E, Varner J A. Nature, 2016, 539(7629): 437-442. doi:10.1038/nature19834http://dx.doi.org/10.1038/nature19834

Chaffer C L, Weinberg R A. Science, 2011, 331(6024): 1559-1564. doi:10.1126/science.1203543http://dx.doi.org/10.1126/science.1203543

Torre L A, Siegel R L, Ward E M, Jemal A. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27. doi:10.1158/1055-9965.epi-15-0578http://dx.doi.org/10.1158/1055-9965.epi-15-0578

Su J, Sun H, Meng Q, Yin Q, Tang S, Zhang P, Chen Y, Zhang Z, Yu H, Li Y. Adv Funct Mater, 2016, 26(8): 1243-1252. doi:10.1002/adfm.201504780http://dx.doi.org/10.1002/adfm.201504780

Shen M, Jiang Y Z, Wei Y, Ell B, Sheng X, Esposito M, Kang J, Hang X, Zheng H, Rowicki M, Zhang L, Shih W J, Celià-Terrassa T, Liu Y, Cristea I, Shao Z M, Kang Y. Cancer Cell, 2019, 35(1): 64-80.e67. doi:10.1016/j.ccell.2018.11.016http://dx.doi.org/10.1016/j.ccell.2018.11.016

Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, Slotta-Huspenina J, Schirbel A, Hänscheid H, Kircher S, Buck A K, Götze K, Vick B, Jeremias I, Schwaiger M, Peschel C, Oostendorp R, Wester H J, Grigoleit G U, Keller U. Theranostics, 2018, 8(2): 369-383. doi:10.7150/thno.21397http://dx.doi.org/10.7150/thno.21397

Gil M, Seshadri M, Komorowski M P, Abrams S I, Kozbor D. Proc Natl Acad Sci USA, 2013, 110(14): E1291-1300. doi:10.1073/pnas.1220580110http://dx.doi.org/10.1073/pnas.1220580110

Jiang J, Shen N, Song W, Yu H, Sakurai K, Tang Z, Li G. Biomater Sci, 2019, 7(12): 5283-5291. doi:10.1039/c9bm01418ghttp://dx.doi.org/10.1039/c9bm01418g

Devine S M, Flomenberg N, Vesole D H, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio J F. J Clin Oncol, 2004, 22(6): 1095-1102. doi:10.1200/jco.2004.07.131http://dx.doi.org/10.1200/jco.2004.07.131

Herbert K E, Demosthenous L, Wiesner G, Link E, Westerman D A, Came N, Ritchie D S, Harrison S, Seymour J F, Prince H M. Bone Marrow Transplant, 2014, 49(8): 1056-1062. doi:10.1038/bmt.2014.112http://dx.doi.org/10.1038/bmt.2014.112

Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee S L, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R. Oncology, 2010, 78(3-4): 282-288. doi:10.1159/000315736http://dx.doi.org/10.1159/000315736

Lee C T, Boss M K, Dewhirst M W. Antioxid Redox Sign, 2014, 21(2): 313-337. doi:10.1089/ars.2013.5759http://dx.doi.org/10.1089/ars.2013.5759

Kessenbrock K, Plaks V, Werb Z. Cell, 2010, 141(1): 52-67. doi:10.1016/j.cell.2010.03.015http://dx.doi.org/10.1016/j.cell.2010.03.015

Lin K Y, Kwon E J, Lo J H, Bhatia S N. Nano Today, 2014, 9(5): 550-559. doi:10.1016/j.nantod.2014.09.001http://dx.doi.org/10.1016/j.nantod.2014.09.001

Sun W, Hu Q, Ji W, Wright G, Gu Z. Physiol Rev, 2017, 97(1): 189-225. doi:10.1152/physrev.00015.2016http://dx.doi.org/10.1152/physrev.00015.2016

Jiang J, Shen N, Ci T, Tang Z, Gu Z, Li G, Chen X. Adv Mater, 2019, 31(44): 1904278. doi:10.1002/adma.201904278http://dx.doi.org/10.1002/adma.201904278

Shen N, Wu J, Yang C, Yu H, Yang S, Li T, Chen J, Tang Z, Chen X. Nano Lett, 2019, 19(11): 8021-8031. doi:10.1021/acs.nanolett.9b03214http://dx.doi.org/10.1021/acs.nanolett.9b03214

Yang S, Tang Z, Hu C, Zhang D, Shen N, Yu H, Chen X. Adv Mater, 2019, 31(11): 1805955. doi:10.1002/adma.201805955http://dx.doi.org/10.1002/adma.201805955

Peer D, Karp J M, Hong S, Farokhzad O C, Margalit R, Langer R. Nat Nanotechnol, 2007, 2(12): 751-760. doi:10.1038/nnano.2007.387http://dx.doi.org/10.1038/nnano.2007.387

Liu Q, Das M, Liu Y, Huang L. Adv Drug Delivery Rev, 2018, 127: 208-221. doi:10.1016/j.addr.2017.09.016http://dx.doi.org/10.1016/j.addr.2017.09.016

Rosenblum D, Joshi N, Tao W, Karp J M, Peer D. Nat Commun, 2018, 9(1): 1410. doi:10.1038/s41467-018-03705-yhttp://dx.doi.org/10.1038/s41467-018-03705-y

Qin S Y, Zhang A Q, Zhang X Z. Small, 2018, 14(45): 1802417. doi:10.1002/smll.201802417http://dx.doi.org/10.1002/smll.201802417

Jain R K, Stylianopoulos T. Nat Rev Clin Oncol, 2010, 7(11): 653-664. doi:10.1038/nrclinonc.2010.139http://dx.doi.org/10.1038/nrclinonc.2010.139

Song W, Tang Z, Zhang D, Li M, Gu J, Chen X. Chem Sci, 2016, 7(1): 728-736. doi:10.1039/c5sc01698chttp://dx.doi.org/10.1039/c5sc01698c

Kulkarni A, Chandrasekar V, Natarajan S K, Ramesh A, Pandey P, Nirgud J, Bhatnagar H, Ashok D, Ajay A K, Sengupta S. Nat Biomed Eng, 2018, 2(8): 589-599. doi:10.1038/s41551-018-0254-6http://dx.doi.org/10.1038/s41551-018-0254-6

Miao Weimin(缪玮珉), Wu Jiasi(巫佳思), Tong Qisong(童其松), Huang Yongcong(黄永聪), Du Jinzhi(杜金志). Acta Polymerica Sinica(高分子学报), 2020, 51(5): 548-558. doi:10.11777/j.issn1000-3304.2020.19227http://dx.doi.org/10.11777/j.issn1000-3304.2020.19227

Shen S, Li H J, Chen K G, Wang Y C, Yang X Z, Lian Z X, Du J Z, Wang J. Nano Lett, 2017, 17(6): 3822-3829. doi:10.1021/acs.nanolett.7b01193http://dx.doi.org/10.1021/acs.nanolett.7b01193

Laoui D, van Overmeire E, de Baetselier P, van Ginderachter J A, Raes G. Front Immunol, 2014, 5: 489. doi:10.3389/fimmu.2014.00489http://dx.doi.org/10.3389/fimmu.2014.00489

Stanley E R, Chitu V. Cold Spring Harb Perspect Biol, 2014, 6(6) : a021857. doi:10.1101/cshperspect.a021857http://dx.doi.org/10.1101/cshperspect.a021857

Wang T, Papoutsi M, Wiesmann M, DeCristofaro M, Keselica M C, Skuba E, Spaet R, Markovits J, Wolf A, Moulin P, Pognan F, Vancutsem P, Petryk L, Sutton J, Chibout S D, Kluwe W. Int J Toxicol, 2011, 30(3): 300-312. doi:10.1177/1091581811401920http://dx.doi.org/10.1177/1091581811401920

Wei Q, Shen N, Yu H, Wang Y, Tang Z, Chen X. Biomater Sci, 2020, 8(20): 5666-5676. doi:10.1039/d0bm00713ghttp://dx.doi.org/10.1039/d0bm00713g

Wang Y, Shen N, Wang Y, Zhang Y, Tang Z, Chen X. Adv Mater, 2021, 33(7): 2002094. doi:10.1002/adma.202002094http://dx.doi.org/10.1002/adma.202002094

Wang Y, Shen N, Wei Q, Tang Z. J Funct Polym, 2020, 33(6): 522-531. doi:10.1016/j.knosys.2020.105594http://dx.doi.org/10.1016/j.knosys.2020.105594

更多指标>

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于枝化多肽的多功能药物递送系统用于肿瘤细胞核的精准靶向治疗